cbdMD Inc. - YCBD Company Value to Revenue Ratio

Official company branding of cbdMD Inc. (YCBD)

The absence of debt at cbdMD, Inc. (YCBD) has ensured an efficient inflow of free cash flow, as confirmed by the base chart on GURU.Markets: the EV/Sales ratio demonstrates current dynamics where the 207.36 metric determines this level. This has solidified the position of US plants within the wellness segment, while outsourcing agro-logistics to external partners has allowed the brand to focus on promotion.

cbdMD Inc. (YCBD) EV/Sales Multiple: for the period 11/23/2025 - 11/20/2026

cbdMD Inc. - analytical breakdowns and key metrics (YCBD)

- share price and expert price forecast:
Initial company analysis:cbdMD Inc., YCBD
Product sample of cbdMD

This indicator determines the market value of the business adjusted for net debt, comparing it to sales volume to identify actual asset overvaluation. For cbdMD, Inc. (YCBD), the price-to-sales multiple trend reflects the resilience of its capitalization against inflationary costs and logistical disruptions in component supplies, allowing investors to assess revenue generation efficiency amid geopolitical risks.

Competitor analysis for cbdMD, Inc.

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|EV/Sales Multiple ABVC (ABVC BioPharma Inc)|CPIX - Company Value to Revenue|Quantum BioPharma Corp - EV/Sales Multiple|FGEN (fibrogen.com) - Company Value to Revenue Ratio|TELO (Telomir Pharmaceuticals) - Company Value to Revenue|Rani Therapeutics Holdings - Business Value to Revenue|Company Value to Revenue SNYR|Enterprise Value-to-Revenue Multiple rallybio.com RLYB|EV/Sales Multiple LEXX|PULM (Pulmatrix, Inc.) - Business Value to Revenue|Pheton Holdings - Company Value to Revenue|EV/Sales Multiple Aptorum Group Limited APM|LYRA: Company Value to Revenue|IBO: Enterprise Value-to-Revenue Ratio|TNFA: EV/Sales Multiple|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio